Wu Tsai Human Performance Alliance
Showing 1-10 of 152 Results
Oliver O. Aalami, MD
Clinical Professor, Surgery - Vascular Surgery
Current Research and Scholarly InterestsWe launched a national precision medicine PAD trial called, VascTrac (http://vasctrac.stanford.edu/). This trial is mobile phone based and leverages Apple's ResearchKit Platform to monitor a patient's activity both pre- and post-intervention. We are validating mobile phone surveillance for PAD patients and are currently enrolling.
Geoffrey Abrams, MD
Associate Professor of Orthopaedic Surgery
Current Research and Scholarly InterestsDr. Abrams' research is focused on elucidating the pathobiology behind tendinoapthy and developing new treatment modalities for the disease. Specifically, his team is studying the role of micro-RNA as it relates to chronic inflammation and stem cell differentiation in the development and perpetuation of chronic tendinopathy.
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsMy research lies in the intersection of Machine Learning, Computer Vision, Healthcare, and Computational Neuroscience.
Al'ai Alvarez, MD, FACEP, FAAEM
Clinical Assistant Professor, Emergency Medicine
BioDr. Al'ai Alvarez FACEP FAAEM is an emergency physician and clinical associate professor of Emergency Medicine (EM) at Stanford University. Dr. Alvarez is the Director of Well-Being and co-chair of the Human Potential Team at Stanford Emergency Medicine. He also serves as the Director of the first Physician Wellness Fellowship. His work focuses on humanizing physician roles as individuals and teams through the harnessing of our individual human potential in the context of high-performance teams. His long-term interest is to optimize the interconnectedness between Medical Education, Process Improvement (Quality and Clinical Operations), Recruitment (Diversity), and Well-being (Inclusion) through human-centered design.
Dr. Alvarez is a faculty fellow at the Stanford Byers Center for Biodesign (2021-2022), exploring the role of mindfulness in high-stress environments. He is also the co-director and organizer for the High-Performance Resuscitation Teams Summit (https://bit.ly/HPRT2022) in May 2022 in Chicago, IL, in collaboration with Mayo Clinic and the Mission Critical Teams Institute. The goal of HPRT is to develop a collaborative inquiry among teams from various disciplines, including healthcare, aerospace, sports, military, special operations forces, fire rescue, and other high-performing/elite teams.
Dr. Alvarez has served as the associate residency program director (APD) at the Stanford Emergency Medicine Residency Program. Among his roles, he served as the second-year class APD and the Medicine Without Walls (MWOW) Line Director for the Stanford Emergency Medicine ACCEL Program (https://emed.stanford.edu/residency/ACCEL.html).
Dr. Alvarez currently also serves as the chair of WellMD's Physician Wellness Forum and is one of the peer supporters for WellMD's Physician Resource Network (PRN) Support.
Nationally, Dr. Alvarez serves on committees on physician well-being and diversity, equity, and inclusion in medical education. He is the co-chair of the Council of EM Residency Directors (CORD) Wellness Leadership Mini-Fellowship, a mentor at the Academic Life in Emergency Medicine (ALiEM) Faculty Incubator, and co-founded and co-chairs the largest national diversity mentoring program in EM through the joint American College of Emergency Physician (ACEP)'s Diversity, Inclusion and Health Equity (DIHE) and the Emergency Medicine Residents Association (EMRA)'s Diversity Mentorship Initiative.
Dr. Alvarez has given numerous grand rounds as well as national and international conference lectures and workshops on relevant topics in gratitude, compassion, and belongingness and their role in physician well-being and diversity, equity, and inclusion in medicine.
Dr. Alvarez is the recipient of the 2019 ACEP DIHE Distance and Impact Award. He is also the recipient of the 2020 Society for Academic Emergency Medicine (SAEM) Academy for Diversity and Inclusion in Emergency Medicine (ADIEM) Outstanding Academician Award. Dr. Alvarez also received the 2020 CORD Academy for Scholarship in Education in EM Academy Member Award on Teaching and Evaluation.
Euan A. Ashley
Associate Dean, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Current Research and Scholarly InterestsThe Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.
Thomas More Storke Professor, Senior Fellow at the Woods Institute for the Environment and Professor, by courtesy, of Education
BioJeremy Bailenson is founding director of Stanford University’s Virtual Human Interaction Lab, Thomas More Storke Professor in the Department of Communication, Professor (by courtesy) of Education, Professor (by courtesy) Program in Symbolic Systems, a Senior Fellow at the Woods Institute for the Environment, and a Faculty Leader at Stanford’s Center for Longevity. He earned a B.A. cum laude from the University of Michigan in 1994 and a Ph.D. in cognitive psychology from Northwestern University in 1999. He spent four years at the University of California, Santa Barbara as a Post-Doctoral Fellow and then an Assistant Research Professor.
Bailenson studies the psychology of Virtual and Augmented Reality, in particular how virtual experiences lead to changes in perceptions of self and others. His lab builds and studies systems that allow people to meet in virtual space, and explores the changes in the nature of social interaction. His most recent research focuses on how virtual experiences can transform education, environmental conservation, empathy, and health. He is the recipient of the Dean’s Award for Distinguished Teaching at Stanford. In 2020, IEEE recognized his work with “The Virtual/Augmented Reality Technical Achievement Award”.
He has published more than 200 academic papers, spanning the fields of communication, computer science, education, environmental science, law, linguistics, marketing, medicine, political science, and psychology. His work has been continuously funded by the National Science Foundation for over 20 years.
Bailenson consults pro bono on Virtual Reality policy for government agencies including the State Department, the US Senate, Congress, the California Supreme Court, the Federal Communication Committee, the U.S. Army, Navy, and Air Force, the Department of Defense, the Department of Energy, the National Research Council, and the National Institutes of Health.
His first book Infinite Reality, co-authored with Jim Blascovich, emerged as an Amazon Best-seller eight years after its initial publication, and was quoted by the U.S. Supreme Court. His new book, Experience on Demand, was reviewed by The New York Times, The Wall Street Journal, The Washington Post, Nature, and The Times of London, and was an Amazon Best-seller.
He has written opinion pieces for Harvard Business Review, The Washington Post, The Wall Street Journal, CNN, PBS NewsHour, Wired, National Geographic, Slate, The San Francisco Chronicle, and The Chronicle of Higher Education, and has produced or directed six Virtual Reality documentary experiences which were official selections at the Tribeca Film Festival. His lab’s research has exhibited publicly at museums and aquariums, including a permanent installation at the San Jose Tech Museum.
Assistant Professor of Chemistry
BioSteven Banik’s research interests center on rewiring mammalian biology and chemical biotechnology development using molecular design and construction. Projects in the Banik lab combine chemical biology, organic chemistry, protein engineering, cell and molecular biology to precisely manipulate the biological machines present in mammalian cells. Projects broadly aim to perform new functions that shed light on regulatory machinery and the potential scope of mammalian biology. A particular focus is the study of biological mechanisms that can be coopted by synthetic molecules (both small molecules and proteins). These concepts are applied to develop new therapeutic strategies for treating aging-related disorders, genetic diseases, and cancer.
Prior to joining the faculty at Stanford, Steven was a NIH and Burroughs CASI postdoctoral fellow advised by Prof. Carolyn Bertozzi at Stanford. His postdoctoral research developed approaches for targeted protein degradation from the extracellular space with lysosome targeting chimeras (LYTACs). He received his Ph.D. from Harvard University in 2016, where he worked with Prof. Eric Jacobsen on synthetic methods for the selective, catalytic difluorination of organic molecules and new approaches for generating and controlling reactive cationic intermediates in asymmetric catalysis.
K. K. Lee Professor, and Professor, by courtesy, of Materials Science and Engineering and of Chemistry
BioZhenan Bao joined Stanford University in 2004. She is currently a K.K. Lee Professor in Chemical Engineering, and with courtesy appointments in Chemistry and Material Science and Engineering. She has been the Department Chair of Chemical Engineering from 2018. She founded the Stanford Wearable Electronics Initiative (eWEAR) and is the current faculty director. She is also an affiliated faculty member of Precourt Institute, Woods Institute, ChEM-H and Bio-X. Professor Bao received her Ph.D. degree in Chemistry from The University of Chicago in 1995 and joined the Materials Research Department of Bell Labs, Lucent Technologies. She became a Distinguished Member of Technical Staff in 2001. Professor Bao currently has more than 700 refereed publications and more than 100 US patents with a Google Scholar H-index 190.
Bao is a member of the US National Academy of Engineering, the American Academy of Arts and Sciences and the National Academy of Inventors. Bao was elected a foreign member of the Chinese Academy of Science in 2021. She is a Fellow of AAAS, ACS, MRS, SPIE, ACS POLY and ACS PMSE.
Bao is a member of the Board of Directors for the Camille and Dreyfus Foundation from 2022. She served as a member of Executive Board of Directors for the Materials Research Society and Executive Committee Member for the Polymer Materials Science and Engineering division of the American Chemical Society. She was an Associate Editor for the Royal Society of Chemistry journal Chemical Science, Polymer Reviews and Synthetic Metals. She serves on the international advisory board for Advanced Materials, Advanced Energy Materials, ACS Nano, Accounts of Chemical Reviews, Advanced Functional Materials, Chemistry of Materials, Chemical Communications, Journal of American Chemical Society, Nature Asian Materials, Materials Horizon and Materials Today. She is one of the Founders and currently sits on the Board of Directors of C3 Nano Co. and PyrAmes, both are silicon valley venture funded companies.
Bao was a recipient of the VinFuture Prize Female Innovator 2022, ACS Award of Chemistry of Materials 2022, MRS Mid-Career Award in 2021, AICHE Alpha Chi Sigma Award 2021, ACS Central Science Disruptor and Innovator Prize in 2020, ACS Gibbs Medal in 2020, the Wilhelm Exner Medal from the Austrian Federal Minister of Science in 2018, the L'Oreal UNESCO Women in Science Award North America Laureate in 2017. She was awarded the ACS Applied Polymer Science Award in 2017, ACS Creative Polymer Chemistry Award in 2013 ACS Cope Scholar Award in 2011. She is a recipient of the Royal Society of Chemistry Beilby Medal and Prize in 2009, IUPAC Creativity in Applied Polymer Science Prize in 2008, American Chemical Society Team Innovation Award 2001, R&D 100 Award, and R&D Magazine Editors Choice Best of the Best new technology for 2001.
Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Associate Professor of Orthopaedic Surgery
Current Research and Scholarly InterestsThe long-term goal of our research is to understand the fundamental mechanisms that govern and reprogram cellular fate during development, regeneration and disease.